CGP 6.78% 6.3¢ consegna group limited

downrampers trying to get app3b, page-11

  1. 3,009 Posts.
    lightbulb Created with Sketch. 157
    Potential earning figures are staggering one really need to read this ann thoroughly also trials have been done with ELITE Athletes not some amateurs from Australia and wanting to buy this.


    "Having finalised the Turbine design with the input of some of Australia's elite athletes we have completed a thorough review of our manufacturing requirements. Choosing a manufacturing partner capable of meeting the growth aspirations of the company was critical. ChinaMed clearly demonstrated an ability to not only meet our needs in our consumer markets, but brings a strong track record of complying with the rigorous regulatory environments of sleep and drug delivery."
    Consegna's Turbine™ nasal dilator technology is set to launch into the Australian online sporting and
    physical recreation goods industry. In 2012-13 industry revenue is estimated to be $765 million, according to IBIS World. In the five years leading up to 2017/18, industry revenue is forecast to grow further by an annualized 6.3% to $1.04 billion. In a recently completed Elite Athlete user trial, the company validated that more than 80% of the respondents reported that they would expect to buy the technology online. The
    Turbine™ nasal dilator delivers 38% more air for both elite and amateur athletes.

 
watchlist Created with Sketch. Add CGP (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.